Recent Vizient CAR T-cell Therapy Findings Highlighted in Medscape Article


An article in Medscape Medical News last month, “'Real World' Data on Costs with CAR-T Cell Therapy,” focused on findings from the Vizient Clinical Data Base that highlighted the high costs and related long hospital stays associated with new chimeric antigen receptor (CAR) T-cell therapies. The findings were presented on Feb. 23 at the 2019 Transplantation & Cellular Therapy (TCT) Meetings in Houston. 

Alyssa Hartsell, MPH, lead analyst and Carina Dolan, PharmD, BCOP, director for clinical oncology and pharmaceutical outcomes at Vizient were both quoted in the article.

To read the full article, click here